Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181150 | 0.85 | CYP19A1 (0.65) | CYP19A1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29791528 | 0.85 | CYP19A1 (0.65) | CYP19A1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5034929 | 0.81 | CYP19A1 (0.74) | CYP19A1PKMALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4315537 | 0.79 | IDO1 (0.60) | CYP19A1PKMALDH1A1CYP2C19SMN1; SMN2 | |
| SCHEMBL15677250 | 0.78 | LMNA (0.53) | CYP19A1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15657199 | 0.78 | LMNA (0.53) | CYP19A1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4334647 | 0.77 | VCAM1 (0.74) | PKMMAPK1CYP2C19SMN1; SMN2IDO1 | |
| SCHEMBL15660246 | 0.76 | ALDH1A1 (0.62) | POLBCYP19A1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL15660010 | 0.75 | MAPT (0.54) | POLBCYP19A1TSHRALDH1A1MAPK1 | |
| SCHEMBL15657633 | 0.75 | LMNA (0.53) | CYP19A1ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653331-B2 | Depleting intracellular reduced glutathione levels in vivo | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | disclosed |
| EP-0909184-B1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | UPJOHN CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030109555-A1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJ0HN COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-0909184-A2 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1998000173-A2 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109555-A1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | GSTP1, GSTA2, GSTA1 | POLB 3460/4885CYP19A1 1235/4885PKM 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.